Smoking, alcohol consumption may lead to prolonged feeding tube use in head and neck cancer
the ONA take:
A recent study found that current smoking and heavy alcohol consumption appear to be risk factors for prolonged use of a gastrostomy tube (GT) in patients with head and neck squamous cell carcinoma (SCC) undergoing radiotherapy or chemoradiotherapy.
This study included patients with head and neck SCC undergoing treatment at a teaching hospital in Ireland; 84 patients were undergoing chemoradiation and 20 patients, radiotherapy alone.
The median duration of GT use was 9 months, and GT use at 12 months was 35%. Risk factors for prolonged GT use was current heavy alcohol consumption and current smoking; however, multivariate analyses showed only current smoking to be an independent risk factor.
The researchers hypothesize that several reasons may explain why smoking and drinking might have an effect. Nicotine may suppress appetite and heavy alcohol consumption may lead to poor motivation to resume eating after treatment.
Further studies would be needed to determine if stopping smoking and drinking can shorten duration of GT use.
Smoking and alcohol consumption are risk factors for use of a gastrostomy tube in head and neck squamous cell carcinoma (SCC).
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|